Connection

William Creasman to Prognosis

Back to Details
This is a "connection" page, showing publications William Creasman has written about Prognosis.
William Creasman
Connection Strength
0.814
Prognosis
  1. Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? Gynecol Oncol. 2016 08; 142(2):278-82.
    View in: PubMed
    Score: 0.093
  2. How valid are current cervical cancer prognostic factors that are used to recommend adjunctive radiation therapy after radical surgery? Am J Obstet Gynecol. 2009 Sep; 201(3):260.e1-3.
    View in: PubMed
    Score: 0.057
  3. Vaginal cancers. Curr Opin Obstet Gynecol. 2005 Feb; 17(1):71-6.
    View in: PubMed
    Score: 0.042
  4. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004 Dec; 95(3):593-6.
    View in: PubMed
    Score: 0.042
  5. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol Oncol. 2004 Feb; 92(2):525-9.
    View in: PubMed
    Score: 0.039
  6. An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med. 1999 Jun-Aug; 44(4):186-92.
    View in: PubMed
    Score: 0.028
  7. HRT and women who have had breast or endometrial cancer. J Epidemiol Biostat. 1999; 4(3):217-20; discussion 221-5.
    View in: PubMed
    Score: 0.028
  8. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. Am J Obstet Gynecol. 1998 Jan; 178(1 Pt 1):62-5.
    View in: PubMed
    Score: 0.026
  9. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
    View in: PubMed
    Score: 0.024
  10. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol. 1997 Feb; 24(1 Suppl 1):S1-140-S1-50.
    View in: PubMed
    Score: 0.024
  11. Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. 2017 04 01; 123(7):1144-1155.
    View in: PubMed
    Score: 0.024
  12. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
    View in: PubMed
    Score: 0.024
  13. The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):264-9.
    View in: PubMed
    Score: 0.022
  14. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.022
  15. Second-look laparotomy in ovarian cancer. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S122-7.
    View in: PubMed
    Score: 0.021
  16. Limited disease: role of surgery. Semin Oncol. 1994 Feb; 21(1):79-83.
    View in: PubMed
    Score: 0.020
  17. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993 Feb 15; 71(4 Suppl):1467-70.
    View in: PubMed
    Score: 0.018
  18. Adenocarcinoma of the uterine corpus. Curr Opin Obstet Gynecol. 1993 Feb; 5(1):80-3.
    View in: PubMed
    Score: 0.018
  19. Recent advances in endometrial cancer. Semin Surg Oncol. 1990; 6(6):339-42.
    View in: PubMed
    Score: 0.015
  20. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group Study). Gynecol Oncol. 1989 Dec; 35(3):378-82.
    View in: PubMed
    Score: 0.015
  21. Prognostic factors in relation to second-look laparotomy in ovarian cancer. Baillieres Clin Obstet Gynaecol. 1989 Mar; 3(1):183-90.
    View in: PubMed
    Score: 0.014
  22. Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. Arch Surg. 1988 Jan; 123(1):42-5.
    View in: PubMed
    Score: 0.013
  23. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987 Oct 15; 60(8 Suppl):2035-41.
    View in: PubMed
    Score: 0.013
  24. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol. 1987 Jan; 26(1):11-8.
    View in: PubMed
    Score: 0.012
  25. Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy. Clin Obstet Gynaecol. 1986 Dec; 13(4):751-65.
    View in: PubMed
    Score: 0.012
  26. Radical hysterectomy as therapy for early carcinoma of the cervix. Am J Obstet Gynecol. 1986 Nov; 155(5):964-9.
    View in: PubMed
    Score: 0.012
  27. Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases. Gynecol Oncol. 1985 Jun; 21(2):220-7.
    View in: PubMed
    Score: 0.011
  28. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol. 1985 Apr 01; 151(7):922-32.
    View in: PubMed
    Score: 0.011
  29. The significance of peritoneal cytology in patients with carcinoma of the cervix. Gynecol Oncol. 1984 Feb; 17(2):139-48.
    View in: PubMed
    Score: 0.010
  30. Immune complexes in ovarian cancer. Gynecol Oncol. 1982 Apr; 13(2):203-12.
    View in: PubMed
    Score: 0.009
  31. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol. 1981 Dec 15; 141(8):921-9.
    View in: PubMed
    Score: 0.008
  32. Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. Gynecol Oncol. 1981 Dec; 12(3):319-27.
    View in: PubMed
    Score: 0.008
  33. Cancer of the endometrium. Curr Probl Cancer. 1980 Aug; 5(2):1-33.
    View in: PubMed
    Score: 0.008
  34. Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol. 1980 Mar; 55(3):363-70.
    View in: PubMed
    Score: 0.008
  35. Adenocarcinoma of the endometrium: its metastatic lymph node potential. A preliminary report. Gynecol Oncol. 1976 Sep; 4(3):239-43.
    View in: PubMed
    Score: 0.006
  36. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul; 13(7):1589-99.
    View in: PubMed
    Score: 0.005
  37. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993 Feb 15; 71(4 Suppl):1702-9.
    View in: PubMed
    Score: 0.005
  38. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993 Jan 15; 71(2 Suppl):606-14.
    View in: PubMed
    Score: 0.005
  39. Preoperative evaluation of patients with recurrent carcinoma of the cervix. Gynecol Oncol. 1972 Nov; 1(1):111-8.
    View in: PubMed
    Score: 0.005
  40. Carcinoma in situ of the cervix. An analysis of 861 patients. Obstet Gynecol. 1972 Mar; 39(3):373-80.
    View in: PubMed
    Score: 0.004
  41. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol. 1971 Jul 15; 110(6):773-81.
    View in: PubMed
    Score: 0.004
  42. Carcinoma of the ovary associated with pregnancy. Obstet Gynecol. 1971 Jul; 38(1):111-6.
    View in: PubMed
    Score: 0.004
  43. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991 Jan; 40(1):55-65.
    View in: PubMed
    Score: 0.004
  44. Prognostic value of peritoneal washings in patients with malignant mixed m?llerian tumors of the uterus. Am J Obstet Gynecol. 1986 Jul; 155(1):83-9.
    View in: PubMed
    Score: 0.003
  45. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986 Mar; 67(3):326-30.
    View in: PubMed
    Score: 0.003
  46. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol. 1985 Sep 15; 153(2):191-6.
    View in: PubMed
    Score: 0.003
  47. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer. 1985 Apr 15; 55(8):1648-53.
    View in: PubMed
    Score: 0.003
  48. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985 Apr 15; 151(8):1009-15.
    View in: PubMed
    Score: 0.003
  49. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol. 1984 Oct 15; 150(4):342-8.
    View in: PubMed
    Score: 0.003
  50. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol. 1984 Sep; 19(1):8-16.
    View in: PubMed
    Score: 0.003
  51. Prognostic value of cytologic examination of peritoneal washings in patients with endometrial carcinoma. Acta Cytol. 1981 Nov-Dec; 25(6):640-6.
    View in: PubMed
    Score: 0.002
  52. Treatment of metastatic trophoblastic disease: good and poor prognosis. Am J Obstet Gynecol. 1973 Feb 15; 115(4):451-7.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.